Free tool
FAERS Monitor: Hemiclor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218647 or its brand name (Hemiclor, Chlorthalidone). Reports on generic versions are filed under their own applications.
Reports
11,713
Serious
7,364
63% of reports
Hospitalization
3,734
Death reported
704
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue916
- nausea758
- drug ineffective755
- diarrhoea700
- dizziness590
- pain567
- off label use561
- headache556
- dyspnoea532
- acute kidney injury474
- chronic kidney disease459
- arthralgia458
- asthenia445
- hypertension406
- blood pressure increased398
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 40 |
| 2006 | 60 |
| 2007 | 44 |
| 2008 | 68 |
| 2009 | 86 |
| 2010 | 127 |
| 2011 | 167 |
| 2012 | 215 |
| 2013 | 218 |
| 2014 | 343 |
| 2015 | 533 |
| 2016 | 661 |
| 2017 | 612 |
| 2018 | 784 |
| 2019 | 941 |
| 2020 | 884 |
| 2021 | 953 |
| 2022 | 1,061 |
| 2023 | 1,007 |
| 2024 | 1,051 |
| 2025 | 1,133 |
| 2026 | 693 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,446 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 459 | 10.9 | 10.0 | 4,111 |
| acute kidney injurySignal | 474 | 5.6 | 5.1 | 1,783 |
| blood pressure increasedSignal | 398 | 4.7 | 4.3 | 1,155 |
| hypertensionSignal | 406 | 3.4 | 3.1 | 709 |
| astheniaSignal | 445 | 2.1 | 1.9 | 269 |
| dizzinessSignal | 590 | 2.1 | 2.0 | 359 |
| fatigueSignal | 916 | 2.1 | 2.0 | 557 |
| arthralgia | 458 | 2.0 | 1.8 | 225 |
| diarrhoea | 700 | 1.9 | 1.8 | 332 |
| nausea | 758 | 1.7 | 1.6 | 237 |
| dyspnoea | 532 | 1.7 | 1.6 | 153 |
| pain | 567 | 1.7 | 1.5 | 152 |
| headache | 556 | 1.6 | 1.5 | 126 |
| off label use | 561 | 1.2 | 1.1 | 11 |
| drug ineffective | 755 | 1.0 | 1.0 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.